The Effect of Advadvanced Glycation Endproducts (AGES) on Bone Formation

Links

Abstract

Bone fragility fractures have been a major concern in the health care of elderly populations. One of the major reasons for fragility fracture is that the structure of bone itself may experience age-related changes, which may affect the normal process of bone remodeling and eventually make bone fragile. Adverse changes in the bone matrix through biochemical modifications like Advanced Glycation End Products (AGEs) are one of such changes that could increase bone fragility. AGEs modify long-lived proteins (e.g. collagen) in a period of weeks and may affect bone cell activities during the remodeling process. In this study, a unique rat implant model with autograft implants was used to mimic in vivo response of bone formation to the matrix AGEs. Bone cores were first dissected from the proximal tibia, then ribosylated to introduce the matrix AGEs and finally implanted back to the counterlateral tibia to observe the bone formation rate. Comparing the control and treated animals after the third week the control group exhibited many more locations where bone formation takes place. Mineral Apposition Rate (MAR) is found around higher in control group. Consequently, overall bone formation rate was found higher in the control group. These results suggest that AGEs may inhibit osteoblast activities during bone formation in rat tibia. Dependency of bone formation on the location of the implant and on the depth in the implant was also studied in this research to observe any relation between the bone formation regions and their orientation. The current results are suggesting that the location of growth plate and availability of more bone marrow in tibia might have a positive correlation with control samples. Finally nano-indentation test was done to evaluate the mechanical properties of the newly formed bone in the vicinity of the core to study if there is any structural changes occurring due to the effect of AGEs and its impact on the overall strength of the bone, yet the results do not suggest any significant difference in the material properties between the control and treated group of specimen.

Cited Works (9)

Year	Entry
1994	Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. August 1994;9(8):1137-1141.
2007	Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem. February 23, 2007;282(8):5691-5703.
1987	Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. December 1987;2(6):595-610.
1993	Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long‐term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. September 1993;8(10):1227-1233.
2006	Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int. March 2006;17(3):319-336.
2009	Villemure I, Stokes IAF. Growth plate mechanics and mechanobiology: a survey of present understanding. J Biomech. August 25, 2009;42(12):1793-1803.
2002	Seeman E. Pathogenesis of bone fragility in women and men. Lancet. May 25, 2002;359(9320):1841-1850.
1997	Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. January 1997;12(1):6-15.
2006	Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. December 2006;17(12):1726-1733.